Aktienanalyse zu Lakewood-Amedex Biotherapeutics Inc (LABT)LABTLakewood-Amedex Biotherapeutics Inc

Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The Company is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The Company is engaged in development of its Bisphosphocin class of antimicrobial agents. The Company is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The Company has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections. It operates in the Healthcare sector.

Lakewood-Amedex Biotherapeutics Inc. (LABT) is not a good buy right now due to its extremely low current price of $0.31, a staggering year-to-date change of -99.70%, and a very low RSI of 7.114 indicating oversold conditions. The company has reported consistent losses, with a net income of -3772008.00 USD in Q2 2026, and a forward P/E ratio of 0, suggesting no earnings growth is expected. Additionally, the stock has seen a 5-day change of -46.55%, reflecting significant downward momentum. The main risk is the company's ongoing financial struggles, as evidenced by its negative EPS of -4.42 and a current ratio of only 0.02, indicating potential liquidity issues.